Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep;35(9):e15727.
doi: 10.1111/dth.15727. Epub 2022 Jul 31.

Severe pemphigoid nodularis successfully treated with dupilumab

Fatma Jendoubi  1 , Chloe Bost  2 , Emilie Tournier  3 , Carle Paul  1 , Maria Polina Konstantinou  1
Affiliations

Severe pemphigoid nodularis successfully treated with dupilumab

Fatma Jendoubi et al. Dermatol Ther. 2022 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Jendoubi Fatma has served as a consultant with honoraria for Sanofi Genzyme, Konstantinou Maria Polina and PAUL Carle have served as investigators for Sanofi Genzyme.

Figures

FIGURE 1
FIGURE 1
(A, B) Pruritic, erythematous, excoriated, papulonodular lesions of the abdomen, upper arms and thighs at initial presentation. (C) Complete response after 4 months of treatment with dupilumab. (D) Direct immunofluorescence showing a linear deposition of IgG and complement at the basement membrane zone. (E) Indirect immunofluorescence on salt‐split skin showing linear deposition of IgG antibodies localized on the blister roof.
See this image and copyright information in PMC

References

    1. Powell AM, Albert S, Gratian MJ, Bittencourt J, Bhogal BS, Black MM. Pemphigoid nodularis (non‐bullous): a clinicopathological study of five cases. Br J Dermatol. 2002;147:343‐349. - PubMed
    1. Lamberts A, Meijer JM, Jonkman MF. Nonbullous pemphigoid: a systematic review. J Am Acad Dermatol. 2018;78:989‐995. - PubMed
    1. Teraki Y, Hotta T, Shiohara T. Skin‐homing interleukin‐4 and‐13‐producing cells contribute to bullous pemphigoid: remission of disease is associated with increased frequency of interleukin‐10‐producing cells. J Invest Dermatol. 2001;117:1097‐1102. - PubMed
    1. Takamura S, Teraki Y. Treatment of bullous pemphigoid with dupilumab: Dupilumab exerts its effect by primarily suppressing T‐helper 2 cytokines. J Dermatol. 2022. doi:10.1111/1346-8138.16428 - DOI - PubMed
    1. Abdat R, Waldman RA, de Bedout V, et al. Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series. J Am Acad Dermatol. 2020;83:46‐52. - PubMed

MeSH terms

Substances